`
`PERIPHERAL
`
`http://w w w .fda.gov/ohrms/dockets/ac/01/briefing/3754b1.htm
`
`Go
`
`41 captures
`1 Jul 01 - 21 Jan 13
`
`AUG
`
`JUN
`
`JUL
`
`1
`
`2000
`
`2001
`
`2002
`
`PERIPHERAL & CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE
`
`June 6, 2001
`
`Briefing Information
`
`Consideratin of NDA 21-196, Xyrem (sodium oxybate, Orphan Medial Inc.), proposed to reduce the incidence of
`cataplexy and to improve the symptom of daytime sleepiness for persons wit narcolepsy.
`
`Orphan Medical Presentations
`
`Disclaimer
`
`The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's
`statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
`
`Briefing Information pdf
`
`Xyrem Prescription and Distribution Process, Video Script 2/2/01) html pdf
`
`Video
`
`FDA Briefing Information
`
`Index pdf
`
`Overview Memo pdf
`
`Efficacy Review pdf
`
`Safety Review pdf
`
`Major Amendment Review pdf
`
`Controlled Substance Overview pdf
`
`https://web.archive.org/web/20010701233052/http://www.fda.gov/ohrms/dockets/ac/01/briefing/3754b1.htm
`
`1/1
`
`Wockhardt 1019